On 18 January 2017 at the World Economic Forum in Davos, Switzerland, the international pharmaceutical industry launched the first-of-its-kind Global Initiative to advance access to non-communicable disease (NCD) prevention and care in low and lower-middle income countries (LICs and LMICs).
According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), NCD-related deaths have reached a point of crisis, particularly in lower and lower - middle income countries, where nearly 80 percent of NCD-related deaths occur. At the same time, in addition to the enormous human losses from non-communicable diseases like cardiovascular diseases, chronic respiratory disease, cancer, diabetes and mental health disorders, there is also economic damage resulting from a reduced working-age population and healthcare system expenses which may amount to US $47 trillion by 2030.
The goal of Access Accelerated, a global project implemented by international pharmaceutical companies in partnership with the World Bank Group and the Union for International Cancer Control (UICC), is to work towards the United Nations 2030 Agenda for Sustainable Development Goal (SDG) to promote the well-being of the population through the development and implementation of measures to reduce premature deaths from NCDs by one-third by 2030.
As a member of IFPMA, the Association of International Pharmaceutical Manufacturers (AIPM) fully supports this initiative, and the issue of improving access to medical care, including for patients suffering from NCDs, is a top priority in the Association's activities. Moreover, AIPM and IFPMA, in partnership with the Ministry of Healthcare of the Russian Federation, conducted two comprehensive researches on NCD prevention and the maintenance of a healthy lifestyle: “Recommendations for the Development and Implementation of Corporate Healthy Lifestyle Programs” (2013-2014) and “Population Attitude to Personal Health: Perception of Health, Understanding of Risk Factors, Morbidity and Mortality” (2010-2011). The results of both studies were highly assessed by professionals and presented on a global level.
“The burden on state budgets allocated to maintain healthcare systems is constantly growing in all countries in line with the number of detected cases of non-communicable diseases, which has become possible due to the availability of modern means and methods of diagnostics. However, there is an obvious gap in the level of medicine availability, including the medicines intended for the treatment and prevention of NCDs, depending on the degree of development of the healthcare system and its financial conditions in a particular country. For this reason, the issue of increasing access to medicines does not lose its relevance and importance, while the healthcare problems remain a priority area for international cooperation. One of the prime examples of the strategic partnership is definitely this global initiative aimed to unite the efforts of the international pharmaceutical industry in order to improve the access to medicinal care to the population in a fight against non-communicable diseases. The Association will keep the Russian public aware of the development and implementation of measures aimed at achieving the goals of this cooperation,” said Vladimir Shipkov, Executive Director of AIPM.
The Association of International Pharmaceutical Manufacturers (AIPM) brings together 60 international companies, which account for over 80% of world pharmaceutical production and more than 60% of the volume of medicines supplied to the Russian Federation.
For additional information, please contact
Legal and Communications Director, AIPM
+7 (495) 933 70 40
Version for printing